Piper Sandler Cuts Achilles Therapeutics (NASDAQ:ACHL) Price Target to $10.00

Achilles Therapeutics (NASDAQ:ACHLGet Rating) had its price target cut by analysts at Piper Sandler from $17.00 to $10.00 in a research report issued to clients and investors on Friday, The Fly reports. Piper Sandler’s price target would indicate a potential upside of 290.63% from the company’s current price.

Separately, Zacks Investment Research cut Achilles Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, May 16th.

Shares of NASDAQ:ACHL traded up $0.08 during midday trading on Friday, reaching $2.56. 1,594 shares of the company’s stock traded hands, compared to its average volume of 88,875. The company has a market cap of $103.94 million, a price-to-earnings ratio of -1.51 and a beta of 0.25. The company has a debt-to-equity ratio of 0.03, a quick ratio of 14.51 and a current ratio of 14.51. Achilles Therapeutics has a one year low of $1.84 and a one year high of $13.00. The stock has a 50 day moving average of $2.59 and a 200 day moving average of $3.69.

Achilles Therapeutics (NASDAQ:ACHLGet Rating) last posted its quarterly earnings data on Tuesday, May 10th. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.06. Sell-side analysts predict that Achilles Therapeutics will post -2.13 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Syncona Portfolio Ltd purchased a new stake in Achilles Therapeutics in the fourth quarter worth about $55,545,000. Point72 Asset Management L.P. increased its position in Achilles Therapeutics by 100.0% in the fourth quarter. Point72 Asset Management L.P. now owns 1,000,000 shares of the company’s stock worth $5,010,000 after buying an additional 500,000 shares in the last quarter. Woodline Partners LP purchased a new stake in Achilles Therapeutics in the fourth quarter worth about $1,625,000. AXA S.A. increased its position in Achilles Therapeutics by 3.8% in the third quarter. AXA S.A. now owns 279,454 shares of the company’s stock worth $2,177,000 after buying an additional 10,319 shares in the last quarter. Finally, BlackRock Inc. increased its position in Achilles Therapeutics by 25.5% in the first quarter. BlackRock Inc. now owns 266,657 shares of the company’s stock worth $784,000 after buying an additional 54,225 shares in the last quarter. Institutional investors and hedge funds own 67.57% of the company’s stock.

Achilles Therapeutics Company Profile (Get Rating)

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma.

Recommended Stories

The Fly logo

Receive News & Ratings for Achilles Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achilles Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.